Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Metabolic Measurements from US Patent US11660306: "Treatment of Rett syndrome"
Assay data:21 Active, 3 Activity ≤ 1 µM, 28 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Potency index, ratio of Sodium orthovanadate IC50 to test compound IC50 for inhibition of N-terminal His-tagged recombinant human PTP1B expressed in Escherichia coli
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Mixed type inhibition of N-terminal His-tagged recombinant human PTP1B expressed in Escherichia coli using pNPP as substrate assessed as inhibition constant preincubated for 15 mins followed by substrate addition and measured after 15 mins by Dixon plot analysis
Assay data:2 Active, 2 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Mixed type inhibition of N-terminal His-tagged recombinant human PTP1B expressed in Escherichia coli assessed as reduction in Vmax with increase in Km using varying concentrations of pNPP as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins by Lineweaver-Burk plot analysis
Inhibition of N-terminal His-tagged recombinant human PTP1B expressed in Escherichia coli
Assay data:9 Active, 12 Tested
Inhibition of PTP1B (unknown origin)
Assay data:3 Tested
Inhibition of recombinant human PTP1B using pNPP as substrate preincubated for 5 mins followed by substrate addition assessed as reduction in p-nitrophenol release
Assay data:5 Active, 7 Tested
Inhibition of recombinant human PTP1B using pNPP as substrate preincubated for 5 mins followed by substrate addition assessed as reduction in p-nitrophenol release at 50 uM relative to control
Assay data:7 Tested
Inhibition of PTP1B (unknown origin) at 15.7 uM relative control
Assay data:3 Active, 3 Tested
Inhibition of human recombinant PTP1B (1 to 322 residues) expressed in Escherichia coli using pNPP as substrate at 36 uM incubated for 10 mins followed by substrate addition and measured after 30 mins by microplate reader based analysis relative to control
Inhibition of human recombinant PTP1B (1 to 322 residues) expressed in Escherichia coli using pNPP as substrate incubated for 10 mins followed by substrate addition and measured after 30 mins by microplate reader based analysis
Assay data:2 Tested
Inhibition of wild-type PTP1B (2 to 435 residues) (unknown origin) using DiFMUP as substrate and measured by biochemical assay
Inhibition of human PTP1B
Assay data:10 Tested
Inhibition of PTP1B (unknown origin) at 10 uM incubated for 30 mins
Inhibition of PTP1B (unknown origin) using pNPP as substrate by spectrophotometer analysis
Inhibition of recombinant human PTP1B expressed in Escherichia coli using p-nitrophenyl phosphate as substrate preincubated for 15 mins followed by substrate addition measured after 60 mins by absorbance based assay
Inhibition of PTP1B (unknown origin) by SpectraMax 340 microplate reader Analysis
Assay data:6 Active, 1 Activity ≤ 1 µM, 6 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human recombinant PTP1B using pNPP as substrate assessed as reduction in p-nitrophenol release incubated for 30 mins by absorbance based analysis
Assay data:1 Active, 1 Activity ≤ 1 µM, 11 Tested
Inhibition of human PTP1B (1 to 321 residues) expressed in Escherichia coli BL21 (DE3) using pNPP as substrate at up to 200 uM preincubated for 4 hrs followed by substrate addition by absorption based analysis
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on